Newsroom

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), presented Phase 1 data today with encouraging efficacy and safety results for its two investigational bicistronic CAR T-cell therapies, KITE-753 and KITE-363, respectively, in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL). The results of the analysis were shared in an oral presentation (Abstract #265) at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. Both KITE-753 and...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced new positive data from its pivotal Phase 2 iMMagine-1 study of anitocabtagene autoleucel (anito-cel), in patients with relapsed or refractory multiple myeloma (RRMM). These data are being presented during an oral presentation at the 67th American Society o...

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), and its partner Arcellx, today announced new positive data from its pivotal iMMagine-1 Phase 2 study of anitocabtagene autoleucel (anito-cel), an investigational agent, which continues to show clinically meaningful deep and durable efficacy with predictable and manageable safety observed to date in relapsed or refractory multiple myeloma (RRMM) patients who had received at least three prior lines of therapy. These new...

COLUMBUS, Ohio--(BUSINESS WIRE)--Worthington Steel, Inc. (NYSE: WS) today issued the following statement: We confirm that we are in negotiations with Klöckner & Co SE about a potential voluntary public takeover offer of Klöckner & Co SE. No investment decision has been made now and the discussions may not result in a transaction. The Company does not intend to comment further. About Worthington Steel Worthington Steel (NYSE:WS) is a metals processor that partners with customers to deliv...

HILLSBORO, Oregon--(BUSINESS WIRE)--Lattice Semiconductor (NASDAQ : LSCC), leader dans le domaine des semi-conducteurs programmables à faible consommation, a annoncé aujourd’hui avoir été sélectionnée comme « Entreprise publique la plus respectée dans le secteur des semi-conducteurs » lors des 2025 Global Semiconductor Alliance (GSA) Awards. Les GSA Awards récompensent les entreprises qui ont fait preuve d’excellence par leur succès, leur vision, leur stratégie et leurs opportunités futures dan...

HILLSBORO, Oregon--(BUSINESS WIRE)--Lattice Semiconductor (NASDAQ: LSCC), leader nel settore dei dispositivi programmabili a basso consumo di potenza, oggi ha annunciato di essere stata selezionata come “Società pubblica di dispositivi a semiconduttori più rispettata” in occasione dei 2025 Global Semiconductor Alliance (GSA) Award, che vengono conferiti alle imprese che hanno dimostrato eccellenza attraverso il successo conseguito, la visione, la strategia e le opportunità sfruttabili nel setto...

HILLSBORO, Oregon--(BUSINESS WIRE)--Lattice Semiconductor (NASDAQ: LSCC), Marktführer im Bereich energieeffizienter programmierbarer Anwendungen, gab heute bekannt, dass das Unternehmen bei den 2025 Global Semiconductor Alliance (GSA) Awards zum „angesehensten börsennotierten Halbleiterunternehmen" gekürt wurde. Mit den GSA Awards werden Unternehmen ausgezeichnet, die durch Erfolg, Vision, Strategie und Zukunftschancen in der Branche Spitzenleistungen erzielt haben, was durch die Abstimmung der...

NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate du...

MENLO PARK, Calif.--(BUSINESS WIRE)--Orca Bio today announced new data presented on its lead investigational allogeneic T-cell immunotherapy, Orca-T, at the 67th ASH Annual Meeting....

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced updated results from two ongoing clinical trials evaluating the efficacy and safety of epcoritamab-bysp, a T-cell engaging antibody administered subcutaneously, as a monotherapy and in combination with other standard of care treatments in adult patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). Results from two arms of the EPCORE® NHL-2 trial, evaluating first-line, fixed-treatment dur...